BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment

被引：280

作者：

Ormerod, LP ^{[1
]}

Milburn, HJ

Gillespie, S

Ledingham, J

Rampton, D

机构：

[1] Blackburn Royal Infirm, Blackburn BB2 3LR, Lancs, England

[2] Guys Hosp, London SE1 9RT, England

[3] St Thomas Hosp, London SE1 9RT, England

[4] UCL Royal Free & Univ Coll Med Sch, Dept Med Microbiol, London NW3 2PF, England

[5] Queen Alexandra Hosp, Portsmouth PO6 3LY, Hants, England

[6] Barts & London NHS Trust, London E1 1BB, England

来源：

THORAX | 2005年 / 60卷 / 10期

关键词：

D O I：

10.1136/thx.2005.046797

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor α (anti-TNF-α) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.

引用

页码：800 / 805

页数：6

共 27 条

[1]

*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_

[2] DISTURBED HEPATIC FUNCTION DURING ISONIAZID CHEMOPROPHYLAXIS - MONITORING HEPATIC FUNCTION OF 427 HOSPITAL EMPLOYEES RECEIVING ISONIAZID CHEMOPROPHYLAXIS FOR TUBERCULOSIS [J].

BAILEY, WC ;

TAYLOR, SL ;

DASCOMB, HE ;

GREENBERG, HB ;

ZISKIND, MM .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1973, 107 (04) :523-529

[3]

*CDC, 2001, MMWR-MORBID MORTAL W, V50, P733

[4]

Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P289

[5] Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].

Choy, EHS ;

Panayi, GS .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916

[6] Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [J].

Gardam, MA ;

Keystone, EC ;

Menzies, R ;

Manners, S ;

Skamene, E ;

Long, R ;

Vinh, DC .

LANCET INFECTIOUS DISEASES, 2003, 3 (03) :148-155

[7]

GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36

[8] Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial [J].

Jasmer, RM ;

Saukkonen, JJ ;

Blumberg, HM ;

Daley, CL ;

Bernardo, J ;

Vittinghoff, E ;

King, MD ;

Kawamura, LM ;

Hopewell, PC .

ANNALS OF INTERNAL MEDICINE, 2002, 137 (08) :640-647

[9]

*JOINT COMM VACC I, 1996, VACC IMM, pCH32

[10]

Keane J, 2002, NEW ENGL J MED, V346, P625

← 1 2 3 →